Insulin-lowering therapeutic modalities for polycystic ovary syndrome.
This article summarizes the relationship between insulin and androgen excess, with a focus on what is known regarding two related issues in polycystic ovary syndrome: (1) defects in insulin secretion in PCOS and their role in the development of glucose intolerance in this population; and (2) pharmacologic interventions designed to attenuate hyperinsulinemia and its sequelae in PCOS.
Ehrmann
D A
DA
Department of Medicine, Pritzker School of Medicine, University of Chicago, Illinois, USA.
D005260:Female; D018149:Glucose Intolerance / Q000209:etiology; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008687:Metformin / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin